Literature DB >> 25871843

Nephrosclerosis: a term in quest of a disease.

Alain Meyrier1.   

Abstract

For a century, nephrosclerosis was ascribed to nonmalignant hypertension and aging. However, it was intuitively perceived that hypertension may follow rather than explain this nephrovasculopathy. Hypertensive nephrosclerosis was long considered a major cause of end-stage renal failure (ESRD). This is especially true in blacks of African descent but not in other ethnic populations. The term 'nephrosclerosis' is still an easy way out to classify a patient with renal insufficiency. This leads to neglect the possibility of an overlooked nephropathy complicated by hypertension and to believe that drastic blood pressure control may retard the progression to ESRD. Several clinical and experimental lines of evidence lead to the understanding that nephrosclerosis, especially in blacks, is a genetic renovasculopathy that precedes the rise in blood pressure. The identification of coding region variants in APOL1 encoding apolipoprotein L-1 in black but also white and Asians opens new lines of research on the genetics of nephroangiosclerosis and of FSGS. Metabolic derangements, such as obesity, oxidative stress, dyslipidemia and atherosclerosis may be considered confounding factors with regard to nephrosclerosis. Histomorphometric studies led to sorting out the lesions due to aging from those stemming from hypertension. They shed new light not only on glomerular lesions that comprise ischemic obsolescence but also on glomerulomegaly and focal-segmental sclerosis, the latter due to a loss of renal autoregulation. It appears that the control of hypertension is not credited with the expected benefit for slowing the decline of renal function. 'Nephrosclerosis' can be considered an umbrella term of poor significance that should be replaced by its pathologic description, that is, arterionephrosclerosis and incite to elucidate the various genetic and metabolic factors that lead to a lesion in quest of a specific disease.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2015        PMID: 25871843     DOI: 10.1159/000381195

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  14 in total

Review 1.  Hypertension-attributed nephropathy: what's in a name?

Authors:  Barry I Freedman; Arthur H Cohen
Journal:  Nat Rev Nephrol       Date:  2015-11-10       Impact factor: 28.314

2.  Evidence of selection as a cause for racial disparities in fibroproliferative disease.

Authors:  Jacklyn N Hellwege; Eric S Torstenson; Shirley B Russell; Todd L Edwards; Digna R Velez Edwards
Journal:  PLoS One       Date:  2017-08-08       Impact factor: 3.240

3.  Blood Pressure and the Risk of Death From Non-cardiovascular Diseases: A Population-based Cohort Study of Korean Adults.

Authors:  Jeoungbin Choi; Jieun Jang; Yoonsuk An; Sue K Park
Journal:  J Prev Med Public Health       Date:  2018-11-14

4.  Gene Expression Studies and Targeted Metabolomics Reveal Disturbed Serine, Methionine, and Tyrosine Metabolism in Early Hypertensive Nephrosclerosis.

Authors:  Marius A Øvrehus; Per Bruheim; Wenjun Ju; Leila R Zelnick; Knut A Langlo; Kumar Sharma; Ian H de Boer; Stein I Hallan
Journal:  Kidney Int Rep       Date:  2018-10-17

5.  Slowly progressive anti-neutrophil cytoplasmic antibody-associated renal vasculitis: clinico-pathological characterization and outcome.

Authors:  Giorgio Trivioli; Seerapani Gopaluni; Maria L Urban; Davide Gianfreda; Matthias A Cassia; Paolo G Vercelloni; Marta Calatroni; Alessandra Bettiol; Pasquale Esposito; Corrado Murtas; Federico Alberici; Federica Maritati; Lucio Manenti; Alessandra Palmisano; Giacomo Emmi; Paola Romagnani; Gabriella Moroni; Gina Gregorini; Renato A Sinico; David R W Jayne; Augusto Vaglio
Journal:  Clin Kidney J       Date:  2020-09-06

Review 6.  Renal Aging: Causes and Consequences.

Authors:  Eoin D O'Sullivan; Jeremy Hughes; David A Ferenbach
Journal:  J Am Soc Nephrol       Date:  2016-11-15       Impact factor: 10.121

7.  Endogenous miR-204 Protects the Kidney against Chronic Injury in Hypertension and Diabetes.

Authors:  Yuan Cheng; Dandan Wang; Feng Wang; Jing Liu; Baorui Huang; Maria Angeles Baker; Jianyong Yin; Rui Wu; Xuanchen Liu; Kevin R Regner; Kristie Usa; Yong Liu; Congxiao Zhang; Lijin Dong; Aron M Geurts; Niansong Wang; Sheldon S Miller; Yongcheng He; Mingyu Liang
Journal:  J Am Soc Nephrol       Date:  2020-06-02       Impact factor: 14.978

8.  Clinical Phenotypes and Long-term Prognosis in White Patients With Biopsy-Verified Hypertensive Nephrosclerosis.

Authors:  Marius A Øvrehus; Tine S Oldereid; Aydin Dadfar; Rune Bjørneklett; Knut I Aasarød; Agnes B Fogo; Joachim H Ix; Stein I Hallan
Journal:  Kidney Int Rep       Date:  2019-12-27

9.  Current findings of kidney biopsy including nephropathy associated with hypertension and diabetes mellitus in Korea.

Authors:  Kipyo Kim; Sang Ho Lee; Sung Woo Lee; Jung Pyo Lee; Ho Jun Chin
Journal:  Korean J Intern Med       Date:  2020-08-14       Impact factor: 2.884

Review 10.  Congestive nephropathy: a neglected entity? Proposal for diagnostic criteria and future perspectives.

Authors:  Faeq Husain-Syed; Hermann-Josef Gröne; Birgit Assmus; Pascal Bauer; Henning Gall; Werner Seeger; Ardeschir Ghofrani; Claudio Ronco; Horst-Walter Birk
Journal:  ESC Heart Fail       Date:  2020-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.